05:39 PM EDT, 05/21/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) said late Tuesday new clinical data from its phase 1b/2a dose-escalation study of EP-104GI to treat eosinophilic esophagitis showed further positive results.

Eosinophilic esophagitis is a disease in which white blood cells migrate into and become trapped in the esophagus, causing pain and difficulty with swallowing food.

"New data from the Resolve trial's first and second cohorts showed good tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects," Eupraxia Chief Executive James Helliwell said.

The company is also seeing data from a third study group indicating improvements in patient-reported symptoms and histological outcomes at 12 weeks, Helliwell said.

Eupraxia shares were up more than 34% in after-hours activity.

Price: 3.8701, Change: +0.99, Percent Change: +34.38